Microbix to Present at Rodman & Renshaw Investor Healthcare Conference. Management to Highlight Pipeline Opportunities.


    TORONTO, Sept. 3 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) announced
today that the Company's Chief Business Officer and Director, Mark Cochran,
PhD, will present at Rodman & Renshaw's 11th Annual Healthcare Conference to
be held at the New York Palace Hotel in New York City September 9 - 11th. The
presentation will take place on Friday, September 11th at 3:40 p.m. in the
Henry Room.
    A webcast of the presentation will be available live and archived at

    Microbix specializes in the development of biological technologies and
commercializing them through global partners. The Company has intellectual
property in large market biotherapeutic drugs, vaccine technologies and animal
reproduction technologies. Established in 1988, Microbix is headquartered in

    This news release is intended for distribution in Canada only and is not
intended for distribution to United States newswire services or dissemination
in the United States. The securities being offered have not been, nor will
they be registered under the United States Securities Act of 1933, as amended,
and may not be offered or sold within the United States or to, or for the
account or benefit of, U.S. persons absent U.S. registration or an applicable
exemption from the U.S. registration requirements. This release does not
constitute an offer for sale of securities in the United States.

    This press release contains forward-looking statements, which are subject
to risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements including
the risks associated with failure to get authorization to release Kinlytic for
distribution in the US from the FDA, inability to complete financing for the
Hunan China project currently the subject of financing; risks associated with
commercializing the pipeline technologies; risks associated with failure to
develop and commercialize SST; non-adoption of SST; risks associated with
currency exchange rates which may exaggerate or reduce the actual financial
performance of the Company. These forward-looking statements represent the
Company's judgment as of the date of this press release. The Company disclaims
any intent or obligation to update these forward-looking statements.

    %SEDAR: 00004220E

For further information:

For further information: visit www.microbix.com or contact William J.
Gastle, CEO, Microbix Biosystems Inc., (416) 234-1624 X 230; James Long, CFO,
Microbix Biosystems Inc., (416) 234-1624 X 265

Organization Profile

Microbix Biosystems Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890